Milestone Posts $80.5M Nine-Month Loss, Cuts 20% of Staff to Extend Runway
MIST is trading near its 52-week low of $0.631 (11% above the low).
Summary
Milestone reported a $80.5 million nine-month net loss as CARDAMYST launch costs surged, and announced a 20% workforce cut plus a PIK-interest amendment to stretch its $145.4 million cash position toward 2028 Phase 3 data.
Key Events · Earnings and Guidance · MIST
-
Restructuring Cuts 20% of Workforce
Announced November 12, 2026, the plan targets a roughly 30% reduction in operating expenses and about $2.0 million in one-time severance charges, mostly in Q4 2026, with the reduction completed in Q1 2027.
-
Nine-Month Net Loss Widens to $80.5M
Net loss was $80.5 million for the nine months ended September 30, 2026 versus $45.6 million a year earlier, driven by SG&A of $67.5 million, up 109.1%.
-
CFO and CMO Depart
CFO Amit Hasija resigned effective November 13, 2026, with VP Finance Anthony Krick named principal financial and accounting officer; Chief Medical Officer David Bharucha was terminated without cause effective November 12, 2026.
-
RTW Note Amendment Allows PIK Interest
The November 11, 2026 fourth amendment lets Milestone defer accrued interest on the $50.0 million 6.0% convertible notes and add it to principal until maturity, preserving cash.
Analysis · MIST · Life Sciences
CARDAMYST's launch is burning cash far faster than planned: SG&A hit $24.2 million in Q3 alone, up 207.2% year over year, pushing the nine-month net loss to $80.5 million against $45.6 million a year earlier. On November 12, 2026, the company responded with a restructuring that cuts roughly 20% of headcount and targets a 30% reduction in operating expenses, intended to carry it through to topline AFib-RVR Phase 3 data expected in the second half of 2028. Against that backdrop the CFO resigned effective today and the Chief Medical Officer was terminated, and the RTW note was amended to let Milestone pay interest in kind rather than cash until maturity. With $145.4 million of cash and investments, the runway is intact, but the pivot from growth spending to retrenchment signals the launch is underperforming internal expectations.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MIST was trading at $0.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $81.6M. The 52-week trading range was $0.63 to $3.06. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.